Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study
Petrylak, Daniel P., Ratta, Raffaele, Matsubara, Nobuaki, Korbenfeld, Ernesto Pablo, Gafanov, Rustem, Mourey, Loic, Todenhöfer, Tilman, Gurney, Howard, Kramer, Gero, Bergman, Andre M., Zalewski, Pawel, De Santis, Maria, Armstrong, Andrew J., Gerritsen, Winald R., Pachynski, Russell Kent, Byun, Seok-Soo, Li, Xin Tong, Schloss, Charles, Poehlein, Christian Heinrich, Fizazi, Karim
Published in Journal of clinical oncology (20.02.2023)
Published in Journal of clinical oncology (20.02.2023)
Get full text
Journal Article
Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Petrylak, Daniel P., Ratta, Raffaele, Matsubara, Nobuaki, Korbenfeld, Ernesto Pablo, Gafanov, Rustem, Mourey, Loic, Todenhöfer, Tilman, Gurney, Howard, Kramer, Gero, Bergman, Andre M., Zalewski, Pawel, De Santis, Maria, Armstrong, Andrew J., Gerritsen, Winald R., Pachynski, Russell Kent, Saretsky, Todd L., Ghate, Sameer R., Li, Xin Tong, Schloss, Charles, Fizazi, Karim
Published in Journal of clinical oncology (20.02.2023)
Published in Journal of clinical oncology (20.02.2023)
Get full text
Journal Article
KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer
Rugo, Hope S., Sohn, Joohyuk, Jerez Gilarranz, Yolanda, Gonzalez-Cortijo, Lucia, Sonnenblick, Amir, Sabanathan, Dhanusha, Korbenfeld, Ernesto Pablo, Egle, Daniel, Poirier, Brigitte, Zagouri, Flora, Matikas, Alexios, Aksoy, Sercan, Demirci, Umut, Ramos-Elias, Pier, Im, Seock-Ah, Cardoso, Fatima, Jia, Liyi, Baccan, Carlos, Tryfonidis, Konstantinos, Schmid, Peter
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1 , BRCA2 or ATM : Results from the PROfound study
Matsubara, Nobuaki, De Bono, Johann S., Olmos, David, Procopio, Giuseppe, Kawakami, Satoru, Urun, Yuksel, van Alphen, Robbert J., Flechon, Aude, Carducci, Michael Anthony, Choi, Young Deuk, Hotte, Sebastien J., Korbenfeld, Ernesto Pablo, Kramer, Gero, Agarwal, Neeraj, Dearden, Simon, Gresty, Christopher, Kang, Jinyu, Poehlein, Christian Heinrich, Harrington, Elizabeth, Hussain, Maha H. A.
Published in Journal of clinical oncology (20.02.2021)
Published in Journal of clinical oncology (20.02.2021)
Get full text
Journal Article